RCUS

Companies
Nyse American
Arcus Biosciences Inc.
Health Care
Price Chart
Overview

About RCUS

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Market Cap
$1.4B
Volume
10.0M
Avg. Volume
9.4M
P/E Ratio
-1.5074946
Dividend Yield
0.00%
Employees
544.0

Company Information

Exchange
Nyse American
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
1.34
High Correlation
Volatility
High (0.62)
Relative to market

Macro Factor Sensitivities

Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for RCUS.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, RCUS shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$1.4B
Volume10.0M
P/E Ratio-1.51
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
February 26, 2025

PortfolioPilot Analysis

Get AI-powered insights on how RCUS fits into your investment strategy and portfolio diversification.

Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025